Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Finished Goods (2023 - 2025)

Ascentage Pharma Group International posted quarterly Finished Goods of $1.0 million for Q4 2025, up 94.81% year-on-year from $537511.9 in Q4 2024, and up 94.81% on a QoQ basis from $537511.9 in Q4 2024.

Ascentage Pharma Group International (AAPG) has 3 years of Finished Goods data on file, last reported at $1.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 94.81% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (up 94.81% YoY), and the FY2025 full-year result was $1.1 million, up 100.38% from the prior year.
  • Finished Goods for Q4 2025 stood at $1.0 million, up from $537511.9 in the prior quarter.
  • Across five years, Finished Goods topped out at $1.5 million in Q4 2023 and bottomed at $537511.9 in Q4 2024.
  • The 3-year median for Finished Goods is $1.0 million (2025), against an average of $1.0 million.
  • The widest annual swing landed in 2024, when Finished Goods plunged 65.06%; it then surged 94.81% in 2025.
  • A 3-year view of Finished Goods shows it stood at $1.5 million in 2023, then slumped by 65.06% to $537511.9 in 2024, then jumped by 94.81% to $1.0 million in 2025.
  • The last three Finished Goods figures came in at $1.0 million (Q4 2025), $537511.9 (Q4 2024), and $1.5 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.05 Mn
Dec 31, 2024 537,511.89
Dec 31, 2023 1.54 Mn